Clarification of Details for Obstetric Management Addition, Endoscopic Surgery Support Device Addition, Heart Failure Readmission Prevention Continuous Management Fee, etc. – Doubt Interpretation 5 [2026 Medical Fee Revision] (1) – GemMed

News Highlights

Doubt Interpretation 5 regarding the 2026 medical fee revision has been released, clarifying details for the Obstetric Management Addition, Endoscopic Surgery Support Device Addition, and Heart Failure Readmission Prevention Continuous Management Fee. This suggests the importance of mid-to-long-term management and succession strategies with an eye on the revision cycle. Furthermore, maintaining facility standards through economies of scale, dispersing the burden of equipment investment, and utilizing tax incentives, including conversion to specific medical corporations or social medical corporations, are raised as points of discussion in M&A and business succession.

Perspective from M&A Medical Editorial Department

This doubt interpretation specifically details the requirements for additions related to particular medical departments and diseases, such as the Obstetric Management Addition and the Heart Failure Readmission Prevention Continuous Management Fee. For instance, the Obstetric Management Addition may involve more detailed evaluations of factors like the number of deliveries, maternal transport records, and collaboration systems with perinatal maternal and child medical centers. This implies that the hurdles for small obstetrics clinics to independently maintain and claim these additions may increase, leading to a greater burden in equipment investment and personnel recruitment. Under these circumstances, group formation through collaboration among multiple medical institutions and sharing management resources, or pursuing economies of scale through M&A, can become essential options for maintaining facility standards and stabilizing profitability. In particular, business succession strategies that consider future equipment investment plans and role allocation within regional medical collaboration will likely be emphasized even more.

Points of Discussion Indicated by This News

• The impact of detailed requirements for the Obstetric Management Addition, Endoscopic Surgery Support Device Addition, and Heart Failure Readmission Prevention Continuous Management Fee on the revenue structure of individual medical institutions.
• The potential for increased burdens in maintaining facility standards for specific additions and introducing/maintaining advanced medical equipment to become management challenges for small medical institutions.
• The necessity of sharing management resources and strengthening profitability through regional medical collaboration promotion corporations or group formation.
• The importance of planned equipment investment and personnel allocation with an eye on future medical fee revisions.

Practical Questions Arising from This News

• With the detailed breakdown of requirements for the Obstetric Management Addition, what are the specific checkpoints to determine if our current system can continue to claim it in the future?
• To what extent can the revenue increase from the addition cover the costs of introducing and maintaining endoscopic surgery support devices? We would like to simulate this.
• What kind of information-sharing system should be established with collaborating medical institutions when claiming the Heart Failure Readmission Prevention Continuous Management Fee?

If You Feel “Should I Consult Too?”

If the content of this revision makes it difficult to claim certain additions or increases the burden of equipment investment, it may become difficult to continue operating independently. Especially for medical institution managers who wish to establish a sustainable management system with an eye on future medical fee revision trends, it is worth considering consulting with experts about comprehensive business succession and growth strategies, including M&A for scale expansion, management efficiency through group participation, and even a review of the medical corporation system.

M&A Medical (CentralMedience Inc.) supports the business succession of medical corporations, hospitals, and clinics as an M&A support institution certified by the Small and Medium Enterprise Agency, with a complete success fee system. Consultations are accepted with strict confidentiality. Free consultation here